Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.

Hajjar A, Ergun MA, Alagoz O, Rampurwala M. Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. PLoS One. 2019; 14(6):e0217778.

View in: PubMed

collapse authors with profiles